Rabacfosadine: Difference between revisions
CSV import |
CSV import |
||
| Line 27: | Line 27: | ||
{{stub}} | {{stub}} | ||
== Rabacfosadine == | |||
<gallery> | |||
File:Rabacfosadine structure.svg|Rabacfosadine structure | |||
</gallery> | |||
Latest revision as of 01:23, 20 February 2025
Rabacfosadine (also known as GS-9219 or VDC-1101) is a prodrug that is used in veterinary medicine for the treatment of lymphoma in dogs. It is a nucleotide analogue that is activated by the enzyme deoxycytidine kinase, which is overexpressed in lymphoid malignancies.
Etymology[edit]
The name "Rabacfosadine" is derived from the chemical structure of the drug. The prefix "Raba" is derived from the name of the company that developed the drug, Rabavert. The suffix "fosadine" is a common suffix used in the names of drugs that are nucleotide analogues.
Pharmacology[edit]
Rabacfosadine is a prodrug, which means it is inactive until it is metabolized in the body. It is activated by the enzyme deoxycytidine kinase, which is overexpressed in lymphoid malignancies. Once activated, Rabacfosadine inhibits DNA synthesis, leading to cell death.
Clinical use[edit]
Rabacfosadine is used in veterinary medicine for the treatment of lymphoma in dogs. It is administered intravenously, usually in a series of treatments over several weeks. The drug has been shown to be effective in inducing remission in dogs with lymphoma, with a response rate of over 70%.
Side effects[edit]
The most common side effects of Rabacfosadine are gastrointestinal symptoms such as vomiting and diarrhea. Other side effects can include decreased appetite, lethargy, and skin reactions at the site of injection. In rare cases, Rabacfosadine can cause severe lung toxicity.
